Xencor
BMS acquires regional rights to Zenasā obexelimab, a bifunctional antibody for autoimmune diseases
Anika Sharma
Zenas BioPharma has made a strategic move by transferring regional rights for its bifunctional monoclonal antibody, obexelimab. Bristol Myers Squibb ...
